Kyle W. Gano

CEO

Board Member

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

Affiliation history

Recorded current and former roles; source labels appear when available.

Recorded roles and earnings-call appearances connecting this person to public companies.

NBIX

Current role

CEO, Board Member

2024-01-01–present

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year	Company	Role	Salary	Bonus	Stock awards	Option awards	Incentive	Other	Total
2025	Neurocrine Biosciences Inc (NBIX)	Chief Executive Officer	$920,000	$966,000	$5,750,023	$5,750,006	—	$62,906	$13,448,935
2024	Neurocrine Biosciences Inc (NBIX)	Chief Executive Officer	$698,217	$536,906	$3,700,106	$3,549,970	—	$50,223	$8,535,422
2023	Neurocrine Biosciences Inc (NBIX)	Chief Executive Officer	$602,912	$331,602	$1,812,563	$3,187,536	—	$55,602	$5,990,215
2022	Neurocrine Biosciences Inc (NBIX)	Chief Executive Officer	$550,605	$332,428	$1,725,086	$2,775,053	—	$38,485	$5,421,657
2021	Neurocrine Biosciences Inc (NBIX)	Chief Business Development and Strategy Officer	$517,000	$271,425	$2,375,067	$2,625,018	—	$22,814	$5,811,324
2020	Neurocrine Biosciences Inc (NBIX)	Chief Business Development and Strategy Officer	$487,700	$207,273	$2,750,208	$3,750,008	—	$16,751	$7,211,940
2019	Neurocrine Biosciences Inc (NBIX)	Chief Development and Strategy Officer	$443,400	$266,040	$1,000,076	$3,000,285	—	$16,171	$4,725,972
2018	Neurocrine Biosciences Inc (NBIX)	Chief Development and Strategy Officer	$403,100	$191,473	$2,656,575	$1,309,024	—	$8,069	$4,568,241

No earnings-call appearances or filed executive changes recorded yet.